FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2508628430> ?p ?o ?g. }

• W2508628430 endingPage "65124" @default.
• W2508628430 startingPage "65109" @default.
• W2508628430 abstract "// Daniela Rovito 1, 2 , Giulia Gionfriddo 1 , Ines Barone 1 , Cinzia Giordano 2 , Fedora Grande 1 , Francesca De Amicis 1 , Marilena Lanzino 1 , Stefania Catalano 1 , Sebastiano Andò 1, 2, * , Daniela Bonofiglio 1, * 1 Department of Pharmacy, Health and Nutritional Sciences, University of Calabria, Rende (CS), Italy 2 Centro Sanitario, University of Calabria, Rende (CS), Italy * Share senior authorship Correspondence to: Sebastiano Andò, email: sebastiano.ando@unical.it Daniela Bonofiglio, email: daniela.bonofiglio@unical.it Keywords: PPARγ, CXCR4, breast cancer, CAF, PPRE Received: May 09, 2016      Accepted: August 11, 2016      Published: August 18, 2016 ABSTRACT Stromal Derived Factor-1α (SDF-1α) and its cognate receptor CXCR4 play a key role in mediating breast cancer cell invasion and metastasis. Therefore, drugs able to inhibit CXCR4 activation may add critical tools to reduce tumor progression, especially in the most aggressive form of the breast cancer disease. Peroxisome Proliferator-Activated Receptor (PPAR) γ, a member of the nuclear receptor superfamily, has been found to downregulate CXCR4 gene expression in different cancer cells, however the molecular mechanism underlying this effect is not fully understood. Here, we identified a novel PPARγ-mediated mechanism that negatively regulates CXCR4 expression in both epithelial and stromal breast cancer cells. We found that ligand-activated PPARγ downregulated CXCR4 transcriptional activity through the recruitment of the silencing mediator of retinoid and thyroid hormone receptor (SMRT) corepressor onto a newly identified PPAR response element (PPRE) within the CXCR4 promoter in breast cancer cell lines. As a consequence, the PPARγ agonist rosiglitazone (BRL) significantly inhibited cell migration and invasion and this effect was PPARγ-mediated, since it was reversed in the presence of the PPARγ antagonist GW9662. According to the ability of cancer-associated fibroblasts (CAFs), the most abundant component of breast cancer stroma, to secrete high levels of SDF-1α, BRL reduced migratory promoting activities induced by conditioned media (CM) derived from CAFs and affected CXCR4 downstream signaling pathways activated by CAF-CM. In addition, CAFs exposed to BRL showed a decreased expression of CXCR4, a reduced motility and invasion along with a phenotype characterized by an altered morphology. Collectively, our findings provide novel insights into the role of PPARγ in inhibiting breast cancer progression and further highlight the utility of PPARγ ligands for future therapies aimed at targeting both cancer and surrounding stromal cells in breast cancer patients." @default.
• W2508628430 created "2016-09-16" @default.
• W2508628430 creator A5002590489 @default.
• W2508628430 creator A5013221500 @default.
• W2508628430 creator A5023763317 @default.
• W2508628430 creator A5042076209 @default.
• W2508628430 creator A5046031758 @default.
• W2508628430 creator A5054597220 @default.
• W2508628430 creator A5054714711 @default.
• W2508628430 creator A5086857323 @default.
• W2508628430 creator A5089369776 @default.
• W2508628430 date "2016-08-18" @default.
• W2508628430 modified "2023-09-29" @default.
• W2508628430 title "Ligand-activated PPARγ downregulates CXCR4 gene expression through a novel identified PPAR response element and inhibits breast cancer progression" @default.
• W2508628430 cites W1077335472 @default.
• W2508628430 cites W1181104234 @default.
• W2508628430 cites W1600620396 @default.
• W2508628430 cites W1607276234 @default.
• W2508628430 cites W1757407923 @default.
• W2508628430 cites W1900016029 @default.
• W2508628430 cites W1964170925 @default.
• W2508628430 cites W1968897950 @default.
• W2508628430 cites W1969850903 @default.
• W2508628430 cites W1976142725 @default.
• W2508628430 cites W1980050427 @default.
• W2508628430 cites W1980237439 @default.
• W2508628430 cites W1983575915 @default.
• W2508628430 cites W1984580148 @default.
• W2508628430 cites W1986986419 @default.
• W2508628430 cites W1987341315 @default.
• W2508628430 cites W1993700321 @default.
• W2508628430 cites W1994512364 @default.
• W2508628430 cites W1995574334 @default.
• W2508628430 cites W2001540049 @default.
• W2508628430 cites W2004280628 @default.
• W2508628430 cites W2012124753 @default.
• W2508628430 cites W2018211174 @default.
• W2508628430 cites W2022048961 @default.
• W2508628430 cites W2023472124 @default.
• W2508628430 cites W2023624246 @default.
• W2508628430 cites W2025199554 @default.
• W2508628430 cites W2031008857 @default.
• W2508628430 cites W2031773477 @default.
• W2508628430 cites W2034255256 @default.
• W2508628430 cites W2036187887 @default.
• W2508628430 cites W2037707039 @default.
• W2508628430 cites W2040920295 @default.
• W2508628430 cites W2044480687 @default.
• W2508628430 cites W2049231891 @default.
• W2508628430 cites W2054211644 @default.
• W2508628430 cites W2060529266 @default.
• W2508628430 cites W2062533841 @default.
• W2508628430 cites W2069412024 @default.
• W2508628430 cites W2069728007 @default.
• W2508628430 cites W2075189068 @default.
• W2508628430 cites W2075261412 @default.
• W2508628430 cites W2078502914 @default.
• W2508628430 cites W2081611139 @default.
• W2508628430 cites W2081921364 @default.
• W2508628430 cites W2086159554 @default.
• W2508628430 cites W2091673549 @default.
• W2508628430 cites W2093463613 @default.
• W2508628430 cites W2097544331 @default.
• W2508628430 cites W2100514340 @default.
• W2508628430 cites W2101037339 @default.
• W2508628430 cites W2102880982 @default.
• W2508628430 cites W2104939091 @default.
• W2508628430 cites W2110956835 @default.
• W2508628430 cites W2116058997 @default.
• W2508628430 cites W2125309270 @default.
• W2508628430 cites W2126414889 @default.
• W2508628430 cites W2126865198 @default.
• W2508628430 cites W2127856718 @default.
• W2508628430 cites W2128645075 @default.
• W2508628430 cites W2141959029 @default.
• W2508628430 cites W2142712029 @default.
• W2508628430 cites W2147427406 @default.
• W2508628430 cites W2152273017 @default.
• W2508628430 cites W2154229564 @default.
• W2508628430 cites W2156323704 @default.
• W2508628430 cites W2156575042 @default.
• W2508628430 cites W2159586731 @default.
• W2508628430 cites W2168972202 @default.
• W2508628430 cites W2208114687 @default.
• W2508628430 cites W2228354790 @default.
• W2508628430 cites W2236340583 @default.
• W2508628430 cites W2261024790 @default.
• W2508628430 cites W60153527 @default.
• W2508628430 doi "https://doi.org/10.18632/oncotarget.11371" @default.
• W2508628430 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5323141" @default.
• W2508628430 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/27556298" @default.
• W2508628430 hasPublicationYear "2016" @default.
• W2508628430 type Work @default.
• W2508628430 sameAs 2508628430 @default.
• W2508628430 citedByCount "49" @default.
• W2508628430 countsByYear W25086284302016 @default.
• W2508628430 countsByYear W25086284302017 @default.
• W2508628430 countsByYear W25086284302018 @default.

• next